^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CGT4859
i
Other names: CGT4859
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Cogent Biosci
Drug class:
FGFR2 inhibitor
Related drugs:
over1year
In vivo characterization of a selective FGFR2 inhibitor with potency against gatekeeper and molecular brake mutations (AACR 2023)
Most importantly, efficacy in a mouse tumor xenograft model at a dose that does not show elevated plasma phosphorus levels in the rat hyperphosphatemia model will be presented. Herein, the in vitro and in vivo characterization of a representative selective reversible FGFR2 inhibitor is described.
Preclinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR fusion • FGFR wild-type • FGFR2 wild-type
|
CGT4859
2years
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations (AACR-NCI-EORTC 2022)
In vivo characterization to be presented includes dose escalating rodent pharmacokinetics, pharmacodynamics in tumor bearing mice, and efficacy in a mouse AN3 CA tumor xenograft model. Herein, the in vitro and in vivo characterization of a representative selective reversible FGFR2 inhibitor is described.
Preclinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR fusion • FGFR wild-type • FGFR2 wild-type
|
CGT4859
Share via
